AAV Vector Formulations with Empty Capsids for Immune Neutralization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Adeno-associated virus (AAV) vectors used in gene therapy often induce immune responses, leading to viral neutralization and limited therapeutic efficacy due to humoral and cytotoxic T cell responses, making it challenging to achieve efficient gene transduction while minimizing vector dose to avoid immune reactions.
Innovation Solution
Formulations comprising predetermined ratios of viral vectors and empty capsids or capsid proteins are administered to inhibit undesired immune responses, with the option of separate or concurrent administration to enhance gene transduction efficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If AAV vectors are administered to achieve gene transduction, then therapeutic polynucleotide delivery is improved, but immune responses are induced leading to viral neutralization and reduced transduction efficiency
Solution Approach 1:
Empty capsids are introduced as intermediary decoy elements that bind to neutralizing antibodies, preventing them from binding to and neutralizing the therapeutic AAV vectors. This intermediary approach allows the therapeutic vectors to evade immune detection and maintain transduction efficiency.
Solution Approach 2:
Empty capsids serve as copies of the viral structure without containing the therapeutic genome. These capsid copies mimic the antigenic properties of the full virus, thereby attracting and binding neutralizing antibodies away from the functional therapeutic vectors.
2Productivity
If vector dose is increased to overcome neutralization, then gene transduction efficiency is improved, but immune responses are intensified
Solution Approach 1:
Empty capsids act as a buffer or intermediary that absorbs excess immune pressure. By providing additional capsid antigens, they allow the system to tolerate higher overall vector doses without proportionally increasing neutralization of therapeutic vectors, thus maintaining transduction efficiency at clinically achievable doses.
3Object-affected harmful factors
If vector dose is reduced to minimize immune reactions, then immune responses are suppressed, but gene transduction efficiency is limited
Solution Approach 1:
The empty capsid copies provide sufficient antigenic mass to engage and neutralize circulating antibodies at lower therapeutic vector doses. This allows the actual therapeutic vectors to be administered at reduced doses while still achieving effective transduction, as the capsid copies have 'soaked up' the neutralizing antibodies.
4Adaptability or versatility
If pre-existing anti-AAV immunity is present, then re-administration capability is reduced, but formulations with empty capsids enable re-administration
Solution Approach 1:
Empty capsids serve as a protective intermediary that shields pre-existing antibodies from neutralizing the therapeutic vectors during re-administration. This allows the system to overcome pre-existing immunity and restore re-administration capability while maintaining therapeutic efficacy.
Data Source
AI summary
The invention provides viral vector formulations and methods of uses thereof for delivery of transgenes or therapeutic nucleic acids to human subjects. The formulations include a vector and suitable amounts of empty capsids, viral genome-containing capsids, or viral capsid proteins which are optionally chemically or structurally modified and which bind to neutralizing anti-AAV antibodies thereby reducing or preventing antibody-mediated clearance of the vector, but still allowing the genome-containing (therapeutic) vector to transduce target cells and achieve therapeutic gene transfer.